Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 7/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191763 | 0.86 | MEN1 (0.61) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL2191761 | 0.86 | MEN1 (0.61) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL13912776 | 0.84 | MEN1 (0.65) | MEN1KMT2ABCHE | |
| SCHEMBL2190718 | 0.83 | MEN1 (0.64) | MEN1KMT2ABCHE | |
| SCHEMBL2190722 | 0.83 | MEN1 (0.64) | MEN1KMT2ABCHE | |
| SCHEMBL5752214 | 0.80 | KCNH2 (0.62) | RAB9ATRPA1BCHEKCNH2 | |
| SCHEMBL5752211 | 0.80 | KCNH2 (0.62) | RAB9ATRPA1BCHEKCNH2 | |
| SCHEMBL13435492 | 0.79 | MEN1 (0.57) | MEN1KMT2ARAB9AMAOBBCHE | |
| SCHEMBL13461850 | 0.77 | MEN1 (0.55) | MEN1KMT2AMAOBMAOABCHE | |
| SCHEMBL18064743 | 0.77 | TRPM8 (0.58) | MEN1KMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671087-B2 | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof | SEPRACOR INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671087-B2 | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof | SEPRACOR INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090163593-A1 | AMINES THAT INHIBIT A MAMMALIAN ANANDAMIDE TRANSPORTER, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-06-25 | — | — | US | disclosed |
| US-20090163593-A1 | AMINES THAT INHIBIT A MAMMALIAN ANANDAMIDE TRANSPORTER, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163593-A1 | AMINES THAT INHIBIT A MAMMALIAN ANANDAMIDE TRANSPORTER, AND METHODS OF USE THEREOF | SLC6A2, HTR2A, SLC18A1 | MEN1 917/4885KMT2A 771/4885RAB9A 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.